293 - L’incremento della concentrazione sierica della proteina S-100 è un marcatore di metastasi nel melanoma maligno? Quattro anni di esperienza
Rivista: Riv Med Lab - JLM, Vol. 5, N. 4, 2004 (SIRSE Srl ed.)
M. Governa, R.M. Dorizzi, A.Tambuscioa, C. Monesea, A. Ferrari, P. Rizzotti, D.Barisoni.
Background. The incidence of malignant melanoma
greatly increased in the recent years and the follow
up of disease is plagued by many relapses. S-100
protein is found in several cells of neuroectodermal
origin. Serum S-100 concentration has been proposed
as biochemical marker in malignant
melanoma since it is related with the progression of
the diasese.
Methods. From October 1999 to October 2003, S-
100 serum concentration was measured in 880 blood
samples obtained from 178 consecutive patients admitted
for histologically confirmed malignant
melanoma S-100 serum concentration was measured
by an assay based on three monoclonal antibodies
against bovine S-100 protein B-subunit, using an automated
chemiluminescence analyzer (Liaison, Diasorin,
Saluggia, Italy). This method is much faster
(requiring less than an hour) compared to the previously
available technology which has been employed
in most of previous studies in this field
Results. Seventeen out of 178 patients (9.55%) had
local or distant metastasis. In 14 of them (82.35%),
S-100 levels were higher then 250 ng/L (decision
level) when disease progression was detected. Furthermore,
five patients showed that a renewed rise of
S-100 concentration reflected a new tumour recurrence.
Conclusions. The present study hints, as previously
reported, the rise of S-100 B protein in serum patients
with malignant melanoma. The modern chemiluminescence
analyser employed in our study is reliable
and fast, allowing to shorten the assay time.